Saturday 17 October 2026
Export KPTI’s income statement to Excel — free account
Karyopharm Therapeutics Inc.
KPTI Healthcare Biotechnology
Karyopharm Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.1 million, up 0.57% from fiscal 2024. In the quarter to June 2026, revenue fell 11.9%, EPS grew 46.3%, free cash flow fell 33.3% and total debt rose 36.6%, each against the same quarter a year earlier.
0.39
0.04
+11.43%
Follow KPTI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.93 | 0.81 | 0.55 | 0.40 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(11.34) | (5.39) | (6.80) | (9.67) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.19 | 1.70 | 1.67 | 1.41 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(7.15) | (4.33) | (3.23) | (2.24) | |
EV/FCF |
(7.14) | (4.32) | (3.23) | (2.24) | |
Quick Ratio |
0.71 | 0.97 | 0.98 | 0.89 | |
Current Ratio |
0.79 | 1.08 | 1.12 | 1.03 | |
Net Debt/EBITDA |
(9.21) | (5.48) | (10.60) | (11.64) | |
Debt/Assets |
224.53% | 170.75% | 209.28% | 196.91% | |
Debt/Equity |
(0.76) | (0.84) | (0.77) | (0.70) | |
Asset Turnover |
1.36 | 1.17 | 1.07 | 1.00 | |
Operating CF/Net income |
0.37 | 1.02 | 0.12 | 0.18 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(1.71) | (2.13) | (1.41) | (1.38) | |
Research and Development Expense of Revenue |
86.61% | 96.38% | 81.18% | 69.35% | |
Selling, General and Administrative Expense of Revenue |
77.52% | 76.10% | 66.82% | 60.41% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.77% | 8.58% | 11.45% | 6.36% | |
Graham Net Nets |
(1.19) | (2.21) | (3.71) | (4.86) | |
Graham Number |
60.32 | 66.27 | 103.94 | 100.69 | |
Earnings Yield |
(145.08%) | (290.39%) | (243.54%) | (221.84%) | |
Free Cash Flow Yield |
(23.16%) | (48.32%) | (93.82%) | (157.85%) | |
Revenue per Share |
1.16 | 1.59 | 3.12 | 5.08 | |
Operating CF per Share |
(0.86) | (1.03) | (1.08) | (0.68) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.86) | (1.03) | (1.08) | (0.68) | |
Cash per Share |
2.25 | 4.13 | 5.83 | 5.29 | |
Shareholders Equity per Share |
(11.41) | (12.07) | (26.79) | (31.06) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(11.41) | (12.07) | (26.79) | (31.06) | |
Free Cash Flow |
(24.93) | (22.73) | (11.83) | (5.86) | |
Working Capital |
(27.85) | 9.03 | 11.09 | 2.59 | |
Net Current Asset Value |
(335.11) | (270.73) | (298.20) | (275.74) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
31.40 | 29.30 | 28.47 | 31.83 | |
Average Payables |
5.13 | 5.08 | 4.56 | 5.59 | |
Average Inventory |
4.49 | 4.18 | 4.39 | 4.32 | |
Average Assets |
108.10 | 129.56 | 136.42 | 142.85 | |
Average Common Equity |
(284.55) | (235.77) | (239.47) | (214.45) |
Columns are period end dates